GlassScriptPhysician profile
Suzanne A Feigofsky
NPI 1598760753
$58,529.91
in general payments reported to CMS, 2019-2025
13 companies · $12K in 2025
The $12K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,134 · 2020: $11K · 2021: $12K · 2022: $3,922 · 2023: $4,935 · 2024: $10K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $9,305 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,625 · Food and Beverage: $6,843 · Consulting Fee: $2,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $9,304.52 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,625.00 |
| Food and Beverage | $6,843.27 |
| Consulting Fee | $2,850.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $28,655.33 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan, Cobalt Dr Mri Surescan |
| Abbott Laboratories | $16,686.78 | 2019-2025 | Ensite Precision, Tacticath Ablation Catheter, Sensor Enabled, Ensite |
| Boston Scientific Corporation | $7,773.08 | 2022-2025 | General - Therapies |
| Lundbeck LLC | $3,586.87 | 2019 | |
| Medtronic Vascular, INC. | $1,295.21 | 2019-2020 | |
| Astellas Pharma US INC | $129.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $123.86 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $117.21 | 2020-2022 | |
| Pfizer INC. | $58.22 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.17 | 2022-2023 | Jardiance |
| Amgen INC. | $33.22 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $13.48 | 2022 | |
| Lemaitre Vascular, INC. | $6.50 | 2023 | Cardiocel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Feigofsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.